This concept is well expressed in the ESMO (European School of Medical Oncology) guidelines [27] in relation to the diversity of the initial treatment intent, suggesting the use of CT doublets and anti-EGFR (panitumumab or cetuximab) when the main objective is a rapid tumor shrinkage. This evidence concerns the gene EGFR and neoplasm.